In This Article:
Phathom Pharmaceuticals (NASDAQ:PHAT) First Quarter 2025 Results
Key Financial Results
-
Revenue: US$28.5m (up by US$26.6m from 1Q 2024).
-
Net loss: US$94.3m (loss widened by 14% from 1Q 2024).
-
US$1.31 loss per share.
We've discovered 4 warning signs about Phathom Pharmaceuticals. View them for free.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Phathom Pharmaceuticals Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) also missed analyst estimates by 15%.
Looking ahead, revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are down 33% from a week ago.
Risk Analysis
Be aware that Phathom Pharmaceuticals is showing 4 warning signs in our investment analysis and 2 of those make us uncomfortable...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.